A carregar...
Clinical Outcomes of Patient Subgroups in the TANGO II Study
INTRODUCTION: Meropenem–vaborbactam (M-V), a new approved antimicrobial, was developed specifically to be effective treatment for the increasingly prevalent and difficult to treat carbapenem-resistant Enterobacterales (CRE) infections. However, registration phase 3 clinical studies offer limited app...
Na minha lista:
| Publicado no: | Infect Dis Ther |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer Healthcare
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7872113/ https://ncbi.nlm.nih.gov/pubmed/33565042 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40121-021-00405-x |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|